The activity of imipenem on Legionella pneumophila, with a note on the treatment of two cases.
An in-vitro assessment of the activity of imipenem, a new carbapenem beta-lactam antibiotic, was undertaken on isolates of Legionella pneumophila. The minimum inhibitory concentrations of imipenem were in the range 0.03 to 0.25 mg/l and turbidimetric studies showed that imipenem had a marked bactericidal effect which was more pronounced than that seen with either rifampicin or erythromycin. Two patients with legionella pneumonia were successfully treated with imipenem as part of a clinical trial of the drug.
D004305:Dose-Response Relationship, Drug; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D015378:Imipenem; D007875:Legionella / Q000187:drug effects*; D007877:Legionnaires' Disease / Q000188:drug therapy*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012293:Rifampin / Q000494:pharmacology; D013845:Thienamycins / Q000494:pharmacology* / Q000627:therapeutic use
D013845:Thienamycins; D004917:Erythromycin; D015378:Imipenem; D012293:Rifampin